AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 114 min read$REPL

Baker Bros. Advisors (NASDAQ: REPL) details 11.8% stake and warrant buys

Baker Bros. Advisors LP and related entities filed Amendment No. 1 to a Schedule 13D for Replimune Group, Inc. (REPL). It describes REPL’s Aug. 9, 2026 offering of 9,701,490 shares at $12.06 and 2,736,340 pre-funded warrants at $12.0599, closing Aug. 11. Funds bought 2,736,340 warrants for about $33.0M.

Original reporting
stocktitan.net
Published Aug 11, 2026, 9:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:07 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
7/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$REPLNeutralMed
01

Why it matters

The key new information is the linkage between the Aug 2026 offering and the reporting persons’ warrant purchases and beneficial ownership framing (11.8% stake referenced in the title). This can affect trading via ownership concentration, potential governance attention, and dilution expectations.

02

Market read

A large disclosed stake and warrant accumulation by a named investor group arrives immediately after the company’s Aug 2026 offering close, a setup that can drive ownership-flow and dilution-sensitive trading.

03

What to watch

Prefunded warrants with very low exercise prices can create future share overhang; traders should watch for subsequent filings that clarify whether the holders intend to push for changes or simply hold for upside.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session positioning following the Aug 11, 2026 offering close and Aug 9 underwriting terms

Background

The text is an Amendment No. 1 to a Schedule 13D for Baker Bros. Advisors and related funds, referencing a recently completed Replimune Group public offering with prefunded warrants.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune Group disclosed a closed Aug 11, 2026 offering, and the filing details Baker Bros. Advisors funds buying 11.8% stake plus 2026 prefunded warrants.

Expected impact

Near-term volatility likely, with downside risk if dilution overhang dominates and upside if investors interpret the stake as a confidence signal.

Evidence & confidence

The article is a Schedule 13D amendment tied to a specific Aug 2026 underwriting and warrant purchases; that combination often changes trading flows and expectations around financing and board strategy.

Market effects

Sector

For biotech small/mid-caps, large prefunded warrant structures can reinforce financing risk premia and increase sensitivity to follow-on activist narratives.

Regional

Limited, primarily US small-cap biotech investor base and NASDAQ liquidity.

Global

Low, as the disclosure is company-specific and not tied to a global macro or cross-border transaction.

Counterpoint

What could challenge this read

The stake build may be largely mechanical around the offering economics (warrants and pricing) rather than a true activist campaign, limiting governance-driven upside.

Key entities

  • issuer
    Replimune Group, Inc.

    NASDAQ-listed biotech company that completed an Aug 11, 2026 public offering of common stock and prefunded warrants.

  • investor
    Baker Bros. Advisors LP

    Reporting person in the Schedule 13D amendment, associated with the disclosed stake and warrant purchases.

  • funds
    667, L.P. and Baker Brothers Life Sciences, L.P.

    Funds that purchased 2026 prefunded warrants in the offering.

Read at source← All news

Related articles

AUG 14
$ABCLMed

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?

AbCellera (ABCL) hit a 52-week high after Phase 2 results for ABCL635 showed an 83% reduction in symptom frequency versus 33% for placebo, and Jones Research raised its price target to $25. Replimune (REPL) reached a 52-week high on a $150M financing. Airbnb (ABNB) rose to a four-year high on Q2 results and a $4.69B-$4.77B Q3 outlook.

stocktwits.com6 min
AUG 14
$REPLHighAI 9/10

Replimune Group, Inc.: Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group (Nasdaq: REPL) reported fiscal Q1 2027 results for the quarter ended June 30, 2026 and said the FDA approved TUDRIQEV (vusolimogene oderparepvec) with nivolumab for unresectable advanced cutaneous melanoma after PD-1 progression. The company expects U.S. launch within 60 days after a $150 million financing. Cash was $195.3M; net loss was $69.8M.

finanznachrichten.de6 min
AUG 14
$REPLHighAI 9/10

Replimune Group, Inc. (REPL): Results of Operations and Financial Condition

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623208d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appoin

SEC EDGAR 8-K6 min
AUG 13
$REPLMedAI 9/10

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

Replimune Group (NasdaqGS: REPL) said the FDA granted accelerated approval for TUDRIQEV (RP1) with nivolumab to treat advanced cutaneous melanoma after prior anti-PD 1 therapy. The company described this as its first FDA approval and expects near-term commercialization, with attention shifting to confirmatory trials and related legal and regulatory matters. The article notes a recent $150m follow-on equity offering.

finance.yahoo.com4 min
AUG 11
$REPLMedAI 8/10

Replimune Prices $150 Million Underwritten Offering

Replimune Group (REPL) priced an underwritten offering of 9,701,490 shares at $12.06 each, plus pre-funded warrants. Gross proceeds are expected at about $150 million before fees. The sale is scheduled to close Aug. 11, 2026. The financing follows REPL’s FDA accelerated approval of TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma.

rttnews.com4 min